Effective immunotherapy of weakly immunogenic solid tumours using a combined immunogene therapy and regulatory T-cell inactivation. (Q39734928)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20186173%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

title

Effective immunotherapy of weakly immunogenic solid tumours using a combined immunogene therapy and regulatory T-cell inactivation (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20186173%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20186173%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

author name string

M C Whelan

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20186173%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

G Casey

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20186173%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

M MacConmara

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20186173%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

J A Lederer

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20186173%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

D Soden

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20186173%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

J K Collins

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20186173%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

G C O'Sullivan

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20186173%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

publication date

26 February 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20186173%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20186173%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20186173%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20186173%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

page(s)

501-511

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20186173%20AND%20SRC:MED&resulttype=core&format=json

Cancer immunotherapy--the endgame begins

18 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.8

Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.8

Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.8

Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.8

Local gene therapy of solid tumors with GM-CSF and B7-1 eradicates both treated and distal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.8

Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.8

CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.8

CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.8

Functional control of regulatory T cells and cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.8

Regulatory T cells and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.8

CD4+ Tregs and immune control

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.8

Suppression of generation of concomitant antitumor immunity by passively transferred suppressor T cells from tumor-bearing donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.8

Regulatory T cells in ovarian cancer: biology and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.8

Tumor cells cotransduced with B7.1 and gamma-IFN induce effective rejection of established parental tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.8

Immune gene therapy as a neoadjuvant to surgical excision to control metastatic cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.8

Rejection of metastatic 4T1 breast cancer by attenuation of Treg cells in combination with immune stimulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.8

Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.8

Depletion of CD4+CD25+ regulatory T cells enhances interleukin-2-induced antitumor immunity in a mouse model of colon adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.8

Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.8

Generation and decay of the immune response to a progressive fibrosarcoma. I. Ly-1+2- suppressor T cells down-regulate the generation of Ly-1-2+ effector T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.8

Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.8

Control of regulatory T cell development by the transcription factor Foxp3

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.8

Regulation of tumour immunity by CD25+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.8

Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.8

Foxp3 programs the development and function of CD4+CD25+ regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.8

Combination B7-Fc fusion protein treatment and Treg cell depletion therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.8

Vaccination against the Forkhead Family Transcription Factor Foxp3 Enhances Tumor Immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.8

The inflammatory response within Dukes' B colorectal cancers: implications for progression of micrometastases and patient survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.8

inferred from DOI database lookup

7 January 2021

based on heuristic

Intra-tumoural regulatory T cells: a potential new target in cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.8

inferred from DOI database lookup

7 January 2021

based on heuristic

Cutting Edge: Anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4+CD25+ T regulatory cells

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.8